Trial Profile
A Single Center, Non-randomized Phase IIa Study of Abraxane in Combination With Cisplatin in Advanced Nasopharyngeal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Oct 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Acronyms ABX-DDP-Dose
- 06 Dec 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 04 Jan 2013 New trial record